Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Lung Neoplasms 1 Liver Neoplasms 1 Head and Neck Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Anus Neoplasms 1

Interventions

enzalutamide 21 Magnetic Resonance Spectroscopy 21 apalutamide 17 Androgen Antagonists 14 Specimen Handling 13 Prednisone 13 Abiraterone Acetate 13 abiraterone 9 Docetaxel 9 Radiotherapy 8 Biopsy 8 darolutamide 7 Radiosurgery 7 Pluvicto 7 Nivolumab 7 cabazitaxel 6 Lutetium-177 6 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6 Lutetium 5 radium Ra 223 dichloride 4 pembrolizumab 4 niraparib 4 gallium 68 PSMA-11 4 cabozantinib 4 bicalutamide 4 atezolizumab 4 Watchful Waiting 4 Surveys and Questionnaires 4 Standard of Care 4 Radiotherapy, Intensity-Modulated 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Radionuclide Imaging × 30 days × Clear all

NCT06003556 2026-06-03

P-GAP

University of Alberta

Phase 2 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡